Welcome to our dedicated page for Exicure news (Ticker: XCUR), a resource for investors and traders seeking the latest updates and insights on Exicure stock.
Exicure Inc (XCUR) is a pioneering biotechnology company developing nucleic acid therapies through its proprietary Spherical Nucleic Acid (SNA) platform. This page serves as the definitive source for verified news and press releases related to the company’s advancements in immunomodulatory treatments, gene silencing innovations, and therapeutic applications across oncology, inflammatory disorders, and neurological conditions.
Access real-time updates on Exicure’s clinical progress, regulatory milestones, and strategic partnerships. Our curated collection includes announcements on SNA technology breakthroughs, trial results, and research collaborations, providing stakeholders with a comprehensive view of the company’s scientific and operational trajectory.
Key content categories include clinical trial updates, regulatory filings, technology licensing agreements, and peer-reviewed research highlights. Each update is structured to help investors and researchers assess Exicure’s position in the competitive biotech landscape while maintaining strict adherence to factual reporting standards.
Bookmark this page for streamlined access to Exicure’s latest developments, and check back regularly for authoritative insights into one of biotechnology’s most innovative nucleic acid delivery platforms.
Exicure has received a delisting determination notice from Nasdaq for not filing its Form 10-K for 2023 and Form 10-Q for Q1 2024 by the extended deadline of May 20, 2024. Trading of Exicure's stock will be suspended on May 30, 2024, unless the company appeals by May 28, 2024. Failure to appeal will result in a Form 25-NSE being filed with the SEC, removing Exicure's securities from Nasdaq. Additionally, Exicure has not held its 2023 Annual Meeting of Stockholders, which is another basis for delisting. Exicure intends to appeal and file the required forms as soon as possible.
Exicure (Nasdaq: XCUR) reported its third-quarter 2023 financial results. The company, which halted all R&D activities in September 2022 to explore strategic alternatives, had cash and equivalents of $0.9 million as of September 30, 2023, down from $8.6 million at the end of 2022, and further decreased to $0.2 million by April 30, 2024.
R&D expenses were $0 for Q3 2023, compared to $4.8 million for the same period in 2022. General and administrative expenses remained steady at $2.4 million. The net loss was $5.3 million, slightly up from $5.2 million in Q3 2022, mainly due to a loss on debt securities.
The company urgently needs additional funding to continue operations, as current cash levels are insufficient.
FAQ
What is the current stock price of Exicure (XCUR)?
What is the market cap of Exicure (XCUR)?
